A non-erythropoietic peptide that mimicks the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. by Patel, Ns et al.
INTRODUCTION
The mortality associated with closed
femur fractures or gunshot wounds to
the abdomen prior to World War I was
50% and 90%, respectively. However,
even with the introduction of the ad-
vanced trauma life support protocol it re-
mains the leading cause of mortality and
morbidity in the United States and is the
number one killer of Americans under
the age of 34 (1). Severe hemorrhage ac-
counts for nearly 40% of all trauma
deaths and is the leading cause of pre-
ventable trauma death (2). If exsanguina-
tion after severe trauma is not the pri-
mary cause of death, then prolonged
shock is known to increase the incidence
of multiple organ failure (MOF) and late
mortality (3). There have been many re-
cent improvements in the care of trauma
hemorrhage including high-ratio transfu-
sion strategies, hypotensive resuscitation,
hemostatic dressings, tourniquets and
novel resuscitation fluids (4). Novel re-
suscitation fluids designed to reduce the
inflammatory response and to improve
patient outcome after trauma are at the
forefront of research in this field.
For 20 years, erythropoietin (EPO) has
been used widely for the treatment of
anemia associated with chronic kidney
disease and cancer chemotherapy (5).
EPO binds and activates a preformed re-
ceptor homodimer (EPO-R) to regulate
the survival, proliferation, and differenti-
ation of erythroid progenitor cells. There
is now good evidence that the effects of
EPO go beyond erythropoiesis: EPO ex-
erts potent antiapoptotic, antioxidant
and angiogenic effects in animal models
M O L  M E D  1 7 ( 9 - 1 0 ) 8 8 3 - 8 9 2 ,  S E P T E M B E R - O C T O B E R  2 0 1 1  |  P A T E L  E T  A L .  |  8 8 3
A Nonerythropoietic Peptide that Mimics the 3D Structure of
Erythropoietin Reduces Organ Injury/Dysfunction and
Inflammation in Experimental Hemorrhagic Shock
Nimesh SA Patel,1 Kiran K Nandra,1 Michael Brines,2 Massimo Collino,3 WS Fred Wong,4 Amar Kapoor,1
Elisa Benetti,3 Fera Y Goh,4 Roberto Fantozzi,3 Anthony Cerami,2 and Christoph Thiemermann1
1Centre for Translational Medicine and Therapeutics, Queen Mary University of London, William Harvey Research Institute, Barts
and The London, London, United Kingdom; 2Araim Pharmaceuticals, Ossining, New York, United States of America; 3Department of
Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy; and 4Department of Pharmacology and
Immunology Program, National University Health System, National University of Singapore, Singapore
Recent studies have shown that erythropoietin, critical for the differentiation and survival of erythrocytes, has cytoprotective
effects in a wide variety of tissues, including the kidney and lung. However, erythropoietin has been shown to have a serious
side effect—an increase in thrombovascular effects. We investigated whether pyroglutamate helix B-surface peptide (pHBSP),
a nonerythropoietic tissue-protective peptide mimicking the 3D structure of erythropoietin, protects against the organ injury/
 dysfunction and inflammation in rats subjected to severe hemorrhagic shock (HS). Mean arterial blood pressure was reduced to
35 ± 5 mmHg for 90 min followed by resuscitation with 20 mL/kg Ringer Lactate for 10 min and 50% of the shed blood for 50 min.
Rats were euthanized 4 h after the onset of resuscitation. pHBSP was administered 30 min or 60 min into resuscitation. HS resulted
in significant organ injury/dysfunction (renal, hepatic, pancreas, neuromuscular, lung) and inflammation (lung). In rats subjected
to HS, pHBSP significantly attenuated (i) organ injury/dysfunction (renal, hepatic, pancreas, neuromuscular, lung) and inflamma-
tion (lung), (ii) increased the phosphorylation of Akt, glycogen synthase kinase-3β and endothelial nitric oxide synthase, (iii) at-
tenuated the activation of nuclear factor (NF)-κB and (iv) attenuated the increase in p38 and extracellular signal-regulated ki-
nase (ERK)1/2 phosphorylation. pHBSP protects against multiple organ injury/dysfunction and inflammation caused by severe
hemorrhagic shock by a mechanism that may involve activation of Akt and endothelial nitric oxide synthase, and inhibition of
glycogen synthase kinase-3β and NF-κB.
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of ischemia-reperfusion injury (brain,
kidney and liver) and local or systemic
inflammation (6–8). The therapeutic use
of high doses of EPO is, however, associ-
ated with side effects, including hyper-
tension (9) and thrombosis (10) which
limit its clinical use.
In a recent prospective, randomized,
placebo-controlled trial that enrolled
1,460 critically ill patients, Corwin and
colleagues reported that EPO (30,000 IU
per week for 3 weeks) reduced 28-d mor-
tality in a subset of trauma patients (n =
402 treated with EPO; n = 391 treated
with vehicle) without affecting the num-
ber of red blood cell transfusions. The
survival advantage afforded by EPO
therapy in trauma patients, however,
was associated with a significant increase
in thrombovascular events (11). It has
been proposed that the beneficial effects
of EPO are secondary to the binding of
EPO to a receptor complex consisting of
EPO-R and the β-common receptor
(CD131) subunit (12), while the above
side effects are due to activation of the
“classic” EPO-R homodimer. Thus, mole-
cules that activate the proposed tissue-
protective receptor without activation of
EPO-R may confer tissue protection
without causing significant side effects.
The proposed tissue-protective recep-
tor exhibits a lower affinity for EPO and
forms distinct molecular species in
crosslinking experiments (13). CD131
also forms receptor complexes with the
α receptor subunits specific for GM-CSF,
IL-3 and IL-5 and has been termed the
“common” receptor (14). We recently
have shown that (i) the helix B of EPO
has tissue-protective properties represen-
tative of the full molecule and (ii) a pep-
tide constructed to mimic the external,
aqueous surface of EPO without primary
sequence similarity (pyroglutamate helix
B surface peptide–pHBSP) mimics, and
possibly accounts for, the protective ef-
fects of EPO in rodent models of ische-
mic stroke and renal ischemia reperfu-
sion injury (IRI) (15).
This study investigates whether
pHBSP attenuates organ injury/
 dysfunction and inflammation in rats
subjected to severe hemorrhagic shock
(HS). Having documented that severe
hemorrhage and resuscitation (HR) in
the rat results in renal dysfunction, he-
patic injury, pancreatic injury, neuromus-
cular injury and lung inflammation, we
have investigated the effect of pHBSP
when given either 30 min or 60 min after
the onset of resuscitation in these ani-
mals. Subsequently, we have investigated
the mechanism(s) underlying the ob-
served beneficial effects of pHBSP in HS
by investigating a number of signaling
pathways which play a role in tissue in-
jury and inflammation, including the
phosphorylation of Akt on Ser473, phos-
phorylation of glycogen synthase kinase-
3β (GSK-3β) on Ser9, phosphorylation of
endothelial nitric oxide synthase (eNOS)
on Ser1177, activation of NF-κB (measured
as nuclear translocation of p65), activa-
tion of p38 MAPK and activation of ex-
tracellular signal-regulated kinase
(ERK)1/2.
MATERIALS AND METHODS
The animal protocols followed in this
study were approved by the local Ani-
mal Use and Care Committee in accor-
dance with the derivatives of both the
Home Office Guidance on the Operation
of Animals (Scientific Procedures) Act
1986 published by Her Majesty’s Station-
ary Office and the Guide for the Care and
Use of Laboratory Animals of the National
Research Council.
Surgical Procedure and Quantification
of Organ Injury/Dysfunction
This study was carried out on 54 male
Wistar rats (Charles River Ltd, Margate,
UK) weighing 230 to 400g receiving a
standard diet and water ad libitum. Rats
were anesthetized with sodium thiopen-
tone, and anesthesia was maintained by
supplementary injections (~10 mg/kg
 intravenously [i.v.]) of sodium thiopen-
tone for the duration of the experiment.
Blood was withdrawn via a cannula in-
serted in the right carotid artery to
achieve a fall in mean arterial pressure
(MAP) to 35 ± 5 mmHg within 10 min.
From this point onwards, MAP was
maintained at 35 ± 5 mmHg for a period
of 90 min, either by further withdrawal of
blood during the compensation phase or
by administration of Ringer Lactate i.v.
during the  decompensation phase. The
average volume of blood withdrawn dur-
ing hemorrhage was 10.13 ± 0.25 ml (n =
40, across all hemorrhaged groups). At 90
min after initiation of hemorrhage, resus-
citation was performed with 20 mL/kg
Ringer Lactate over a period of 10 min,
and then half the shed blood mixed with
100 IU/ mL heparinized saline over a pe-
riod of 50 min. At the end of 1 h resusci-
tation, an i.v. infusion of Ringer Lactate
(1.5 mL/ kg/h) was started as fluid re-
placement and maintained throughout
the experiment for a further 3 h, at which
point 1.2-mL blood samples were col-
lected via the carotid artery into S/1.3
tubes containing serum gel (Sarstedt,
Numbrecht, Germany), after which the
heart was removed to terminate the ex-
periment. The samples were centrifuged
(6000g for 3 min) to separate serum from
which creatinine, aspartate aminotrans-
ferase (AST), alanine aminotransferase
(ALT), lipase and creatine kinase were
measured within 24 h (IDEXX Laborato-
ries Ltd., West Yorkshire, UK). Addition-
ally, lung and kidney samples were taken
and stored at –80°C for further analysis.
Experimental Design
Rats were allocated randomly into the
following groups: (i) Sham (n = 10); (ii)
Sham + pHBSP 60 min after resuscitation
(n = 4); (iii) HS + saline (n = 10); (iv) HS +
pHBSP 0 min after resuscitation (pHBSP
1 μg/kg, i.v. administered 0 min after the
onset of resuscitation, n = 10); (v) HS +
pHBSP 30 min after resuscitation (pHBSP
1 μg/kg, i.v. administered 30 min after
the onset of resuscitation, n = 10); (vi)
HS + pHBSP 60 min after resuscitation
(pHBSP 1 μg/kg, i.v. administered
60 min after the onset of resuscitation,
n = 10) and (vii) HS + pHBSP 90 min
after resuscitation (pHBSP 1 μg/kg, i.v.
administered 90 min after the onset of
 resuscitation, n = 10). The volume of
saline (vehicle) administered was equal
to the volume of pHBSP administered
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(1 mL/kg). Sham-operated rats under-
went identical surgical procedures but
without hemorrhage or resuscitation.
Histology
At the end of the experiment, lung
samples were excised and fixed in 10%
(w/v) formalin, buffered with phosphate
buffered saline (PBS, 0.01 M, pH 7.4) for
1 wk. Samples then were dehydrated
using graded ethanol, embedded in
paraffin wax and cut into sections using
a Leica rotary microtome (thickness,
5 μm). Sections were deparaffinized with
xylene, stained with Gills hematoxylin
and washed. Sections then were subse-
quently counterstained with 1% eosin,
dehydrated with ethanol and cleared
with Neo-Clear (Darmstadt , Germany)
before mounting using HistoMount (At-
lanta, GA, USA). Sections were analyzed
using a Leica DM2000 upright micro-
scope (Wetzlar, Germany). To determine
lung injury, the sections were examined
blind using a grading scale (0: none, 1:
rare, 2: mild, 3: moderate and 4: severe)
as described by Akinci OI et al. (16) with
minor modifications. Features examined
were inflammatory cell infiltration, pul-
monary congestion and thickening of the
alveolar septa. A total of ten fields were
evaluated randomly for each sample.
The score for each group was the aver-
age score for all samples in the group.
Western Blot Analysis
Western blots were carried out as de-
scribed previously (17). Three separate
experiments of Western blot analysis
were performed for each marker, and tis-
sues were done separately for each West-
ern blot experiment. Briefly, rat liver and
kidney samples were homogenized and
centrifuged at 4,000g for 5 min at 4°C.
Supernatants were removed and cen-
trifuged at 15,000g at 4°C for 40 min to
obtain the cytosolic fraction. The pelleted
nuclei were resuspended in extraction
buffer. The suspensions were centrifuged
at 15,000g for 20 min at 4°C. The result-
ing supernatants containing nuclear pro-
teins were removed carefully, and pro-
tein content was determined using a
bicinchoninic acid (BCA) protein assay
following the manufacturer’s directions.
Proteins were separated by 8% sodium
dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and trans-
ferred to a polyvinyldenedifluoride
(PVDF) membrane, which then was incu-
bated with a primary antibody (rabbit
anti-ICAM-1, rabbit anti–total GSK-3β,
dilution 1:200; goat anti-pGSK-3β Ser9
dilution 1:200; rabbit anti–total Akt dilu-
tion 1:1,000; mouse anti-pAkt Ser473 dilu-
tion 1:1,000; rabbit anti–total eNOS dilu-
tion 1:200; goat anti-peNOS Ser1177
dilution 1:200; rabbit anti-NF-κB p65 di-
lution 1:400; rabbit anti–total ERK1/2 di-
lution 1:2,000; mouse anti–phospho
ERK1/2 dilution 1:2,000; mouse
anti–phospho p38, dilution 1:1,000; rabbit
anti–total p38 dilution 1:1,000). Blots then
were incubated with a secondary anti-
body conjugated with horseradish peroxi-
dase (dilution 1:10,000) and developed
using the ECL detection system. The im-
munoreactive bands were visualized by
autoradiography. The membranes were
stripped and incubated with β-actin mon-
oclonal antibody (dilution 1:5,000) and
subsequently with an antimouse antibody
(dilution 1:10,000) to assess gel-loading
homogeneity. Densitometric analysis of
the bands was performed using Gel Pro
Analyzer 4.5, 2000 software (Media Cy-
bernetics, Silver Spring, MD, USA) and
optical density analysis was expressed as
fold-increase versus the sham group. In
the sham group, the immunoreactive
bands of the gel were respectively mea-
sured and normalized against the first im-
munoreactive band (standard sham sam-
ple) and the results of all the bands
belonging to the same group were ex-
pressed as mean ± SEM. This provides
SEM for the sham group where a value of
one is relative to the first immunoreactive
band. The membranes were stripped and
incubated with β-actin monoclonal anti-
body and, subsequently, with an anti-
mouse antibody to assess gel-loading ho-
mogeneity. Relative band intensity was
assessed and normalized against parallel
β-actin expression. Each group was then
adjusted against corresponding sham data
to establish relative protein expression
when compared with sham animals.
Materials
Unless otherwise stated, all com-
pounds used in this study were pur-
chased from Sigma-Aldrich Company
Ltd. (Poole, Dorset, UK). All stock solu-
tions were prepared using nonpyrogenic
saline (0.9% [w/v] NaCl; Baxter Health-
care Ltd., Thetford, Norfolk, UK). Ringer
Lactate was purchased from Baxter
Healthcare Ltd. Antibodies for Western
blot analysis were purchased from Santa
Cruz Biotechnology, Inc. (Heidelberg,
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Figure 1. Effect of pHBSP on mean arterial pressure; mean arterial pressure was monitored
throughout HR in rats subjected to sham operation (Sham, n = 10; Sham + pHBSP 60 min
post after resuscitation [1 μg/kg 60 min after the onset of sham resuscitation], n = 4) or HS
(HS + saline, n = 10; HS + pHBSP 0 min after resuscitation [1 μg/kg 0 min after the onset of
resuscitation], n = 5; HS + pHBSP 30 min after resuscitation [1 μg/kg 30 min after the onset
of resuscitation], n = 10; HS + pHBSP 60 min after resuscitation [1 μg/kg 60 min after the
onset of resuscitation], n = 10; HS + pHBSP 90 min after resuscitation [1 μg/kg 90 min after
the onset of resuscitation], n = 5). Data represent mean ± SEM for n observations, P < 0.05
sham versus HS + saline.
Germany). pHBSP was supplied by
Araim Pharmaceuticals Inc. (Ossining,
NY, USA).
Statistical Analysis
All values described in the text and
figures are expressed as mean ± standard
error of the mean (SEM) for n observa-
tions. Each data point represents bio-
chemical measurements obtained from
up to 10 separate animals. For histologi-
cal scoring, each data point represents
analysis of kidneys taken from four indi-
vidual animals. Statistical analysis was
carried out using GraphPad Prism 5.0d
(GraphPad Software, San Diego, Califor-
nia, USA). Data without repeated meas-
urements was assessed by one-way
ANOVA followed by the Dunnett post
hoc test. Data with repeated measure-
ments was assessed by two-way ANOVA
followed by the Bonferroni post hoc test.
A P value of less than 0.05 was consid-
ered to be significant.
RESULTS
Effect of pHBSP on the Circulatory
Failure Caused by Hemorrhagic
Shock
When compared with sham-operated
rats, HS rats treated with vehicle demon-
strated a significant reduction in MAP
during the resuscitation period (Fig-
ure 1). The administration of pHBSP at
either 0, 30, 60 or 90 min after the onset
of resuscitation failed to attenuate the
decline in MAP caused by hemorrhage
during the resuscitation phase (see Fig-
ure 1).
Effect of pHBSP on the Multiple Organ
Failure Caused by Hemorrhagic
Shock
When compared with sham-operated
rats, HS rats treated with vehicle devel-
oped significant increases in serum crea-
tinine (Figure 2A), AST (Figure 2B), ALT
(Figure 2C), lipase (Figure 2D) and crea-
tine kinase (Figure 2E) indicating the
 development of renal dysfunction, liver
injury, pancreatic injury and skeletal-
muscle injury. Treatment of HS rats with
pHBSP (60 min into resuscitation) signifi-
cantly attenuated the rises in serum crea-
tinine (see Figure 2A), AST (see Fig-
ure 2B), ALT (see Figure 2C) and creatine
kinase (see Figure 2E), and abolished the
rise in serum lipase (see Figure 2D).
However, treatment of HS rats with
pHBSP (0 or 90 min into resuscitation)
failed to significantly attenuate the rises
in serum creatinine, AST, ALT, lipase and
creatine kinase (Figure 2). Thus, treat-
ment of HS rats with pHBSP as late as
60 min into resuscitation attenuated the
multiple organ injury/dysfunction
caused by HS.
Hemorrhage frequently is associated
with acute lung injury and acute respira-
tory distress syndrome (ARDS) (18).
When compared with sham-operated
rats (Figures 3A, 4A), the lung histology
of HS rats treated with vehicle confirmed
inflammatory cell infiltration (P < 0.05,
Figures 3B, D), alveolar septal thickening
(Figures 3B, E) and pulmonary conges-
tion (Figures 4B, D), suggesting develop-
ment of lung injury/inflammation. Treat-
ment of HS rats with pHBSP (60 min into
resuscitation) significantly attenuated the
degree of inflammatory cell infiltration
(Figures 3C, D) and alveolar septal thick-
ening (Figures 3C, E) and reduced pul-
monary congestion (Figures 4C, D). To
confirm this further, when compared
with sham-operated rats (Figure 3F), HS
rats treated with vehicle demonstrated a
significant increase in the expression of
lung ICAM-1 protein (see Figure 3F).
Treatment of HS rats with pHBSP
(60 min into resuscitation) significantly
attenuated the increase in the expression
of ICAM-1 caused by HS (see Figure 3F).
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Figure 2. Effect of pHBSP on renal function (A); serum creatinine levels, liver injury (B,C);
serum aspartate aminotransferase and alanine aminotransferase levels, pancreatic injury
(D); serum lipase levels, and neuromuscular injury (E); serum creatine kinase levels were
measured after sham operation (Sham, n = 10; Sham + pHBSP 60 min after resuscitation
[1 μg/kg 60 min after the onset of sham resuscitation], n = 4) or HS (HS + saline, n = 10; 
HS + pHBSP 0 min after resuscitation [1 μg/kg 0 min after the onset of resuscitation], n = 5;
HS + pHBSP 30 min after resuscitation [1 μg/kg 30 min after the onset of resuscitation], n =
10; HS + pHBSP 60 min after resuscitation [1 μg/kg 60 min after the onset of resuscitation],
n = 10; HS + pHBSP 90 min after resuscitation [1 μg/kg 90 min after the onset of resuscita-
tion], n = 5). Data represent mean ± SEM for n observations, P < 0.05 HS + saline.
Effect of pHBSP on the Phosphorylation
of Akt, GSK-3β and eNOS in the Livers
and Kidneys of Rats that Underwent
Hemorrhage and Resuscitation
To gain a better insight into the poten-
tial mechanism(s) underlying the ob-
served beneficial effects of pHBSP, we
investigated the effects of this peptide
on cell signaling pathways known to
confer tissue protection or to inhibit in-
flammation in liver and kidney. When
compared with sham-operated rats, HS
rats treated with vehicle developed sig-
nificant decreases in the phosphoryla-
tion of Akt on Ser473 and GSK-3β on Ser9
in liver and kidney (Figures 5A–D).
Treatment of HS rats with pHBSP atten-
uated (30 or 60 min into resuscitation)
the decline in the phosphorylation of
Akt and GSK-3β caused by HR in both
liver and kidney (see Figures 5A–D). The
degree of the phosphorylation of eNOS
on Ser1177 was similar in sham-operated
rats and HS rats treated with vehicle in-
dicating that HR alone is not sufficient
to affect eNOS phosphorylation (Figures
5E, F). Treatment of HS rats with pHBSP
(60 min in kidney and 30 and 60 min
into resuscitation in the liver) resulted in
a significant increase in the phosphory-
lation of eNOS when compared with HS
rats treated with vehicle alone (see Fig-
ures 5E, F).
Effect of pHBSP on the Nuclear
Translocation of the p65 NF-κB Subunit
in the Livers and Kidneys of Rats that
Underwent Hemorrhage and
Resuscitation
When compared with sham-operated
rats, HS rats treated with vehicle devel-
oped significant increases in the nuclear
translocation of the p65 NF-κB subunit in
both liver and kidney indicating the acti-
vation of NF-κB (Figure 6). Treatment of
HS rats with pHBSP (60 min into resusci-
tation) resulted in a significant reduction
in nuclear translocation of p65 and,
hence, the activation of NF-κB in both
liver and kidney (see Figure 6).
Effect of pHBSP on the Phosphorylation
of p38 in the Livers and Kidneys of
Rats that Underwent Hemorrhage and
Resuscitation
When compared with sham-operated
rats, HS rats treated with vehicle exhib-
ited significant increases in the phospho-
rylation of p38 in liver and kidney (Fig-
ures 7A, B). Treatment of HS rats with
pHBSP did not affect p38 phosphoryla-
tion in the kidney (see Figures 7A, B).
Treatment of HS rats with pHBSP (30 or
60 min into resuscitation) did, however,
attenuate the degree of p38 phosphoryla-
tion in the liver significantly (see Fig-
ures 7A, B).
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Figure 3. Effect of pHBSP on lung injury and inflammation. Lung histological sections taken
from a sham-operated rat with inflammatory cell infiltration grade 1 and no observable
alveolar septa thickening (A); a rat subjected to HS with inflammatory cell infiltration grade
3 and widespread alveolar septa thickening (B); and a rat subjected to HS and adminis-
tered 1 μg/kg pHBSP 60 min after the onset of resuscitation with inflammatory cell infiltration
grade 2 and focal alveolar septa thickening (C). Hematoxylin and eosin, magnification ×
100, Figures are representative of at least three experiments performed on different days. Ef-
fect of pHBSP on lung inflammatory cell infiltration (D), alveolar septal thickening (E) and
ICAM-1 expression, corrected for the corresponding β-actin content and normalized using
the related sham band (F), after sham operation (Sham, n = 3) or HS (HS + saline, n = 3; HS +
pHBSP 60 min after resuscitation [1 μg/kg 60 min after the onset of resuscitation], n = 3).
Data represent mean ± SEM for n observations, P < 0.05 HS + saline.
Effect of pHBSP on the Phosphorylation
of ERK1/2 in the Livers and Kidneys of
Rats that Underwent Hemorrhage and
Resuscitation
When compared with sham-operated
rats, HS rats treated with vehicle devel-
oped significant increases in the phos-
phorylation of ERK1/2 in the liver and
kidney (Figures 7C, D). Treatment of HS
rats with pHBSP (30 or 60 min into resus-
citation) attenuated the increase in ERK
phosphorylation caused by hemorrhage
and resuscitation in both organs (see Fig-
ures 7C, D).
DISCUSSION
There is now substantial evidence that
EPO protects organs and tissues against
a number of noxious stimuli including is-
chemia (6). In 2004, we discovered that
the administration of EPO (300 IU/kg)
on resuscitation reduces the organ
 injury/dysfunction associated with se-
vere trauma hemorrhage by antiapop-
totic and antiinflammatory mechanisms
(19). Although EPO also improved sur-
vival in critically ill patients with
trauma, this came at the expense of a sig-
nificant increase in thrombotic events
(11). The recent discovery of a nonery-
thropoietic, tissue-protective peptide
mimicking the 3D structure of EPO
(pHBSP) allowed us to test the hypothe-
sis that the tissue- protective effects of
EPO can be obtained in trauma hemor-
rhage in the absence of significant side
effects. We report here that a single injec-
tion of pHBSP given intravenously to
rats after the onset of resuscitation atten-
uated the renal dysfunction, liver injury,
pancreatic injury and neuromuscular in-
jury caused by severe HR in the anes-
thetized rat. There is evidence that EPO
attenuates the degree of lung inflamma-
tion and injury caused by hyperoxic in-
jury (20), ischemia-reperfusion (21) and
acute necrotizing pancreatitis (22). We re-
port here that pHBSP attenuated the de-
gree of inflammatory cell infiltration,
alveolar septal thickening and congestion
in the lungs of rats subjected to HR.
Thus, similar to EPO, pHBSP exerts tis-
sue-protective and antiinflammatory ef-
fects in vivo.
What, then, is the mechanism(s) by
which pHBSP exerts these beneficial ef-
fects? Clearly, pHBSP affected neither the
metabolic acidosis nor the hemodynamic
abnormalities caused by HR. There is
some evidence that the beneficial effects
of EPO are secondary to the activation of
the survival kinase Akt (23,24). Akt is a
member of the phosphoinositide 3-kinase
signal transduction enzyme family, which
regulates cellular activation, inflammatory
responses, chemotaxis and apoptosis (25).
When phosphorylated by its upstream
regulator, phosphoinositide -dependent ki-
nase, Akt modulates cell survival and
growth (25). We report here that HR re-
sults in a significant reduction in the
phosphorylation of Akt in both the liver
and kidney. A reduction in the activation
of this important survival pathway will
make organs more susceptive to injury
and inflammation (26,27). Most notably,
pHBSP restored the degree of Akt phos-
phorylation to the level seen in sham-
 operated animals even when the EPO-
mimetic was given as late as 60 min into
resuscitation. Both EPO and pHBSP also
enhance the phosphorylation of Akt in
cardiomyocytes subjected to TNF-α (28).
GSK-3β is a serine-threonine kinase
that originally was recognized as a ki-
nase that phosphorylates glycogen syn-
thase. In contrast to most other kinases,
GSK-3β is active in a resting cell state;
however, it is inactivated by phosphory-
lation of Ser9. GSK-3β is regulated by
multiple signaling pathways including
the Akt pathway, which inactivates it by
causing Ser9 phosphorylation (29,30).
Consistent with decline in the phospho-
rylation/activation of Akt reported here,
HR also caused a significant decline in
the phosphorylation of GSK-3β on Ser9.
This indicates an excessive activation of
GSK-3β which would drive both inflam-
mation (31) and tissue-injury (32). Simi-
lar to the above-reported effects on Akt
phosphorylation, pHBSP restored the de-
gree of Ser9 phosphorylation on GSK-3β
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Figure 4. Effect of pHBSP on pulmonary congestion. Lung histological sections taken from
a sham-operated rat with congestion grade 0 (A); a rat subjected to HS with congestion
grade 3 (B); and a rat subjected to HS and administered 1 μg/kg pHBSP 60 min after the
onset of resuscitation with congestion grade 0 (C). Hematoxylin and eosin, magnification
400×, figures are representative of at least three experiments performed on different days.
Effect of pHBSP on pulmonary congestion (D) after sham operation (Sham, n = 3) or HS
(HS + saline, n = 3; HS + pHBSP 60 min after resuscitation [1 μg/kg 60 min after the onset of
resuscitation], n = 3). Data represent mean ± SEM for n observations, P < 0.05 HS + saline.
to the levels seen in sham-operated ani-
mals even when the EPO-mimetic was
given as late as 60 min into resuscitation.
An increase in Ser9 phosphorylation re-
sults in inhibition of this kinase and in-
hibitors of GSK-3β exert potent antiin-
flammatory (31,33) and antiischemic
effects in a number of organs (32,34,35).
Interestingly, inhibition of GSK-3β also
mediates the cardioprotective effects of
EPO (32).
Downstream of GSK-3β, several stud-
ies have now reported an association be-
tween GSK-3β and NF-κB activity in vitro
(36,37) and in vivo (31,38). NF-κB is a
transcriptional factor that plays an im-
portant role in regulating the transcrip-
tion of a number of genes, especially
those involved in producing mediators
involved in local and systemic inflamma-
tion, such as cytokines, chemokines, cell
adhesion molecules, apoptotic factors
and other mediators (39). Treatment of
TNF-α stimulated hepatocytes with a
specific GSK-3β inhibitor resulted in a
decrease of the NF-κB–dependent gene
transcription (40). This study also indi-
cated four potential phosphorylation
sites for GSK-3β on the NF-κB subunit
p65. Most notably, pretreatment with a
number of chemically distinct inhibitors
of GSK-3β attenuates organ injury and
dysfunction caused by hemorrhage and
resuscitation and endotoxemia (31,33).
This protective effect was associated with
inhibition of the activation of NF-κB and
NF-κB–dependent proinflammatory
genes, along with a reduced phosphory-
lation of Ser536 on the NF-κB p65 subunit.
In addition, GSK-3β also may inhibit the
activation of NF-κB by phosphorylating
and degrading IκBα, which is required to
prevent NF-κB translocation (37). We re-
port here that HR results in a significant
increase in the activation of NF-κB (mea-
sured here as nuclear translocation of
p65) which was attenuated when pHBSP
was given 60 min into resuscitation. All
of the above findings support the view
that pHBSP restores the activation of
Akt, resulting in inhibition of GSK-3β
(after phosphorylation on Ser9) and inhi-
bition of the activation of NF-κB.
In addition to inhibiting the activation
of GSK-3β, activation of Akt results in
the phosphorylation of eNOS on Ser1177
which, in turn, causes activation of eNOS
resulting in an enhanced formation of ni-
tric oxide (NO). In our study, HR did not
affect eNOS phosphorylation on Ser1177.
Administration at 60 min into resuscita-
tion of pHBSP, however, caused a pro-
nounced increase in eNOS phosphoryla-
tion and, hence, activity. In conditions
associated with ischemia-reperfusion in-
jury, activation of eNOS is beneficial as
the enhanced formation of NO causes
local vasodilation, inhibits adhesion of
platelets and neutrophils and regulates
angiogenesis (41). There is good evidence
that agents which release NO or enhance
the formation of endogenous NO attenu-
ate organ injury/dysfunction in HS (42).
Agents that also inhibit the formation of
NO from inducible NOS (iNOS) also at-
tenuate the multiple organ failure associ-
ated with HS (43). Inhibition of eNOS ac-
tivity also attenuates the cardioprotective
effects of EPO (44). Recently, Su et al. (45)
have demonstrated that CD131, when ac-
tivated by EPO, is able to activate Akt
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Figure 5. Effect of pHBSP on the phosphorylation of Ser473 on Akt in the liver (A) and kidney
(B), Ser9 on GSK-3β in the liver (C) and kidney (D), and Ser1177 on eNOS in the liver (E) and
kidney (F) after sham operation (Sham, n = 4) or HS (HS + saline, n = 4; HS + pHBSP 30 min
after resuscitation [1 μg/kg 30 min after the onset of resuscitation], n = 4; HS + pHBSP 60
min after resuscitation [1 μg/kg 60 min after the onset of resuscitation], n = 4). Data repre-
sent mean ± SEM for n observations, P < 0.05 HS + saline.
Activation of p38 MAPK promotes cel-
lular stress responses such as prolifera-
tion, differentiation and production of
proinflammatory cytokines and occurs in
response to ischemia and hemorrhage in
a number of organs (46,47). HR results in
the activation of p38 MAPK (in male ani-
mals), while inhibition of the activity of
this p38 MAPK in hemorrhagic shock at-
tenuates renal, cardiac and lung injury
(48–50). We report here that HR results in
a moderate activation of p38 MAPK
(even when measured at 4 h after onset
of resuscitation) in the kidney and a
more marked activation in the liver, the
latter of which was attenuated by pHBSP
when given either at 30 or 60 min into re-
suscitation. Our data are consistent with
the hypothesis that prevention of the ac-
tivation of p38 MAPK contributes to the
observed beneficial effects of pHBSP, at
least, in the liver. It is well documented
that activation of p38 peaks 1 h after
hemorrhage in the kidney and thereafter
gradually declines. Thus, it is possible
that a more marked activation of p38
MAPK occurs early after hemorrhage
which may have been attenuated by
pHBSP.
Like ischemia, severe HR results in the
activation of ERK1/2 and drugs that pre-
vent the activation of ERK1/2 in HS
exert beneficial effects (51). We report
here that the activation of both ERK1/2
caused by HR is attenuated by pHBSP.
Like trauma hemorrhage, traumatic
brain injury results in a significant acti-
vation of ERK1/2 which drives brain
edema. Interestingly, EPO attenuates
brain edema in this model by preventing
the activation of ERK1/2 (52). Similarly,
the beneficial effects of EPO in a rat
model of spinal cord injury have been at-
tributed to the ability of EPO to reduce
the phosphorylation of ERK (53).
In conclusion, we have discovered that
the nonhematopoietic EPO-analogue
pHBSP attenuates the multiple organ in-
jury and dysfunction when given during
resuscitation of rats subjected to severe
hemorrhage. It should be noted that
pHBSP was still effective when given as
late as 60 min after the onset of resuscita-
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Figure 6. Effect of pHBSP on NF-κB activation in the liver (A) and kidney (B) after sham op-
eration (Sham, n = 4) or HS (HS + saline, n = 4; HS + pHBSP 30 min after resuscitation [1
μg/kg 30 min after the onset of resuscitation], n = 4; HS + pHBSP 60 min after resuscitation
[1 μg/kg 60 min after the onset of resuscitation], n = 4). Data represent mean ± SEM for n
observations, P < 0.05 HS + saline.
Figure 7. Effect of pHBSP on the phosphorylation of p38 in the liver (A) and kidney (B), and
ERK-1/2 in the liver (C) and kidney (D) after sham operation (Sham, n = 4) or HS (HS + saline,
n = 4; HS + pHBSP 30 min after resuscitation [1 μg/kg 30 min after the onset of resuscitation],
n = 4; HS + pHBSP 60 min after resuscitation [1 μg/kg 60 min after the onset of resuscitation],
n = 4). Data represent mean ± SEM for n observations, P < 0.05 HS + saline.
and, in turn, increases the interaction be-
tween CD131 and eNOS. This increase in
interaction results in the activation of
eNOS and production of NO (45). Thus,
activation of eNOS (possibly secondary
to activation of Akt) may contribute to
the beneficial effects of pHBSP reported
here.
tion. Surprisingly, some of the effects (on
outcome or signaling) observed with
pHBSP were more pronounced when the
peptide was given at 60 min, rather than
30 min, into the resuscitation period. We
have reported previously that the effi-
cacy of pHBSP increased when given as
late as 6 hours after the onset of reperfu-
sion of the previously ischemic kidney
(15). We do not fully understand this
phenomenon, but it is possible that the
receptor targeted by pHBSP (and EPO) is
upregulated in response to injury, lead-
ing to a more pronounced response after
binding of the ligand. In addition, phar-
macokinetic studies have confirmed that
pHBSP has a very short plasma half life
of ~2 min in the rat (15) suggesting that
an agent present within the circulation
for only a short time after i.v. dosing elic-
its protective effects equivalent to EPO or
CEPO with plasma half lives of 4–6 hours.
Whatever the mechanism, this finding is
likely to be of therapeutic relevance, as it
allows a late intervention in HS and other
conditions associated with  ischemia-
reperfusion. This could be of great im-
portance when aiming to extend the
“golden hour” after a major insult.
The acute model used here necessitates
the use of heparin to prevent the forma-
tion of clots in the catheters used to ex-
tract the blood as well as the hemor-
rhaged blood. It has been known for
some time that heparin does have poten-
tial therapeutic applications beyond anti-
coagulation (54) and these should be
considered when evaluating data from
this model. However, the model used
here demonstrates significant multiple
organ failure (MOF) compared with ani-
mals subjected to sham operation, sug-
gesting that the dose of heparin used
here to prevent coagulation does not pro-
duce any observable beneficial effects.
To gain a better insight into the signal-
ing pathways involved in the tissue-
 protective and/or antiinflammatory ef-
fects of pHBSP, we have investigated 
the effects of pHBSP on signaling path-
ways known to play a role in tissue
 injury/survival and/or inflammation. As
the time-course in the activation of these
signaling cascades may vary between tis-
sues, we have carried out these mecha-
nistic studies in both liver and kidney,
two organs that were markedly protected
by pHBSP, in the hope to find common
signaling events that contribute to the
observed beneficial effects of pHBSP in
vivo. In both liver and kidney, HR re-
sulted in a significant inactivation of the
survival kinase Akt (measured as reduc-
tion in the phosphorylation on Ser473).
Treatment of rats with pHBSP restored
the phosphorylation and, hence, activa-
tion of Akt, which, in turn, resulted in in-
hibition of GSK-3β (secondary to phos-
phorylation on Ser9) and inhibition of the
activation of NF-κB. There is now very
good evidence that therapeutic strategies
which enhance the activation of Akt and
reduce the activation of GSK-3β enhance
the resistance of organs to noxious stim-
uli (including ischemia) and reduce in-
flammation via inhibition of NF-κB (37).
Activation of Akt by pHBSP also resulted
in activation of eNOS (measured as
phosphorylation on Ser1177) which should
result in an enhanced formation of NO in
the microcirculation. In addition, pHBSP
attenuated the HR-induced activation of
p38 MAPK and ERK1/2, both of which
are known to contribute to the develop-
ment of organ injury/inflammation in
HS (49,51). We propose that all of the
above signaling events initiated by
pHBSP contribute to the beneficial effects
of this nonhematopoietic EPO analogue
in HS. As the beneficial effects of EPO in
patients with trauma are limited by side
effects owing to excessive erythropoiesis,
we speculate that nonhematopoietic ana-
logues of EPO such as pHBSP may be
useful to mimic the tissue-protective ef-
fects of EPO without causing the well
documented side effects.
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